Atazanavir

Articles · Medicine Compliance Aid Stability · Lactation Safety Information · New Medicines ·

413591007

Articles

Medicine Compliance Aid Stability

Reyataz · Bristol-Myers Squibb Pharmaceutical Ltd

Bristol-Myers Squibb Pharmaceutical Ltd
Reyataz
Capsules 150mg, 200mg, 300mg
A1 · Amber 1 · Stability data is available in an alternative container (not CAs) that may be extrapolated to support storage in CAs.
No special precautions for storage
No special precautions for storage.
3rd August 2015

Lactation Safety Information

Specialist drug/complex disease area for which expert advice is recommended

New Medicines

Reyataz · HIV infection in children aged at least 3 months of age and weighing at least 5 kg - 50mg oral powder

Information

Reyataz
New formulation
Bristol-Myers Squibb
Bristol-Myers Squibb

Development and Regulatory status

Licensed but not launched
Licensed but not launched
None
Jan 18 · BMS has no plans to market this formulation in the UK [4].
Jul 16 · Licence variation approved in EU [3].
Apr 16 · EU positive opinion for a new oral powder formulation for use, co-administered with low dose ritonavir, and in combination with other antiretroviral medicinal products, to treat HIV-1 infected paediatric patients at least 3 months of age and weighing at least 5 kg [1].

Category

Azapeptide protease inhibitor
In 2005, the estimated vertical transmission rate in infants born in the UK to women infected with HIV was less than 4%. 120 children aged under 16 years were diagnosed as HIV-positive [2].
HIV infection in children aged at least 3 months of age and weighing at least 5 kg - 50mg oral powder
Oral

Evidence based evaluations